key: cord-0683500-ug7kq8b5 authors: Thiele, Thomas; Ulm, Lena; Holtfreter, Silva; Schönborn, Linda; Kuhn, Sven Olaf; Scheer, Christian; Warkentin, Theodore E.; Bröker, Barbara M.; Becker, Karsten; Aurich, Konstanze; Selleng, Kathleen; Hübner, Nils-Olaf; Greinacher, Andreas title: Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2 date: 2021-05-18 journal: Blood DOI: 10.1182/blood.2021012217 sha: ff395b647b3a8796ef8c006b955c0e9e53306ff8 doc_id: 683500 cord_uid: ug7kq8b5 Vaccination using the adenoviral vector COVID-19 vaccine ChAdOx1 nCoV-19(AstraZeneca) has been associated with rare vaccine-induced immune thrombotic thrombocytopenia(VITT). Affected patients test strongly positive in PF4/polyanion enzyme immunoassays (EIAs) and serum-induced platelet activation is maximal in the presence of PF4. Wedeterminedthe frequency of anti-PF4/polyanionantibodies in healthy vaccinees andassessed whether PF4/polyanionEIA-positive sera exhibit platelet-activating propertiesafter vaccination with ChAdOx1 nCoV-19 (n=138) orBNT162b2 (BioNTech/Pfizer; n=143). In total, 19 of 281 participants tested positive for anti-PF4/polyanion antibodies post-vaccination (All:6.8% [95%CI, 4.4-10.3]; BNT162b2: 5.6% [95%CI, 2.9-10.7]; ChAdOx1 nCoV-19: 8.0% [95%CI, 4.5-13.7%]).Optical densities were mostly low (between 0.5-1.0 units; reference range, <0.50) and none of the PF4/polyanionEIA-positive samples induced platelet activation in the presence of PF4. We conclude that positive PF4/polyanionEIAs can occur after SARS-CoV-2 vaccination with both mRNA- and adenoviral vector-based vaccines, but the majority of these antibodies likely have minor (if any) clinical relevance.Accordingly, low-titer positive PF4/polyanion EIA results should be interpreted with caution when screening asymptomatic individuals after vaccination against Covid-19.Pathogenic platelet-activating antibodies that cause VITT do not occur commonlyfollowing vaccination.  Low-titer PF4/polyanion antibodies occur after vaccination with ChAdOx1 nCoV-19 and BNT162b2  These PF4/polyanion antibodies do not activate platelets and may have little relevance for the diagnosis of VITT Accordingly, low-titer positive PF4/polyanion EIA results should be interpreted with caution when screening asymptomatic individuals after vaccination against Covid-19. Pathogenic platelet-activating antibodies that cause VITT do not occur commonly following vaccination. Vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are a cornerstone in controlling the SARS-CoV-2 pandemic [1] [2] [3] [4] Antibodies of VITT patients bind to PF4 alone, but also to PF4 in PF4/heparin complexes. If VITT is suspected, a screening test for PF4/polyanion antibodies is recommended 5,10 to confirm the presence of high-titer anti-PF4 antibodies. It is well known from HIT that anti-PF4/polyanion antibodies among heparin-exposed patients are heterogeneous, with only a minority of IgG exhibiting strong heparin-dependent platelet-activating properties. Further, preexisting B-cells exist which can produce anti-PF4 antibodies. These B-cells are present even in cord blood 11 . But activation of these B-cells requires an appropriate antigen and additional co-signals. The frequency of these antibodies is especially high in patients after major surgery indicating that tissue trauma and/or inflammation 12 provide an important co-signal for induction of anti-PF4 antibody production. After vaccination against Covid-19, 4 inflammatory responses including fever, chills and headaches are frequently reported. This raises the question how frequently platelet-activating anti-PF4/polyanion IgG occur after vaccination against Covid-19 and whether there is a difference between vector-based and mRNA-based vaccines. Vaccination of health care workers was performed between January and March 2021 in an institutional program of the University Medicine of Greifswald (UMG Importantly, none of the sera testing EIA-positive for anti-PF4/polyanion antibodies could reproducibly activate platelets in a platelet activation assay in the presence of added PF4. Two sera tested initially weakly/borderline positive, but negative on repeat testing. Of note, platelet-activating antibodies could not be excluded in the two 6 positive participants of the AICOVI study, because samples were collected in EDTA. However, ODs were low (OD: 0.7-0.8). The frequency of positive anti-PF4/polyanion IgG tests in our study appears higher than observed in healthy blood donors. Hursting, et al., found a frequency of 6.6% seropositive anti-PF4/polyanion samples among 3.795 blood donors 15 ** tested were only participants with positive PF4/polyanion EIA after vaccination who had an available baseline sample before vaccination. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Efficacy and Safety of the mRNA-1273 SARS-CoV-2 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination Autoimmune heparin-induced thrombocytopenia Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH Further insights into the anti-PF4/heparin IgM immune response The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4 Platelet factor 4/heparin antibodies in blood bank donors Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study